BACKGROUND AIMS: @entity1386 ( @entity1386 )-derived mesenchymal stromal cells (MSC) ( @entity1386 -MSC) represent a novel tool for delivering therapeutic genes to @entity5 cells. @entity12421 is a cytokine with pleiotropic cellular functions, including anti-proliferative, immunomodulatory and anti-angiogenic activities. The purpose of this study was to engineer @entity235 @entity1386 -MSC (cAT-MSC) producing @entity12421 and to evaluate the anti- @entity5 effect of cAT-MSC- @entity12421 combined with @entity900 in @entity19 @entity320 model. METHODS: cAT-MSC engineered to express @entity19 @entity12421 were generated using a lentiviral vector (cAT-MSC- @entity12421 ) and the secreted @entity12421 -induced @entity5 cell growth and apoptosis on @entity19 cells was investigated in vitro prior to in vivo studies. Melanoma-bearing @entity19 was developed by injecting @entity19 cells subcutaneously into 6-week-old C57BL/6 @entity19 . After 14 days, @entity900 (10 mg/kg) was injected intratumorally, and 3 days later the engineered cAT-MSC were injected subcutaneously every 3 days to @entity204 . @entity5 volume and survival times were measured. RESULTS: The combination treatment of cAT-MSC- @entity12421 with @entity900 was more effective in inhibiting the growth of @entity320 and resulted in significantly extended survival time than both an unengineered cAT-MSC- @entity900 combination group and a @entity900 -alone group. Interestingly, subcutaneously injected cAT-MSC- @entity12421 were migrated to @entity5 sites. CONCLUSIONS: Our data suggest that @entity235 @entity1386 -MSC could serve as a powerful cell-based delivery vehicle for releasing therapeutic proteins to @entity5 lesions. Maximal anti- @entity5 effects were seen when this therapy was combined with a DNA-damaging chemotherapeutic agent. This study demonstrates the possible applicability of @entity1386 -MSC-mediated @entity12421 in treating @entity235 and @entity1 @entity5 @entity1 .

Anti- @entity5 effects of @entity235 adipose tissue-derived mesenchymal stromal cell-based interferon-b gene therapy and @entity900 in a XXXX @entity320 model.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Tumor', 'inhibition of tumor'] @entity235 :: ('9615', 'Species') :: ['canine'] @entity19 :: ('10090', 'Species') :: ['mice', 'B16F10', 'mouse'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity12421 :: ('15977(Tax:10090)', 'Gene') :: ['IFN-b', 'Interferon (IFN)-b'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1386 :: ('MESH:D018205', 'Disease') :: ['AT', 'Adipose tissue']
@entity19 :: (10090,Species) :: ['mouse']
